A bold ablation bet with early commercial momentum
- Pulse is built around nsPFA, a short electric pulse method meant to clear cells without burning or freezing tissue.
- The company reported $434,000 of Q2 2026 product revenue from limited market release sales of Vybrance.
- Pulse expects to complete its pivotal NANOPULSE-AF catheter trial in October 2026 after very fast enrollment.
- The balance sheet holds over $100 million in cash after a recent stock sale, reducing immediate funding risks.
- Robert W. Duggan controls over 71 percent of the company, which gives one insider very high influence.
Great tech, early proof
Pulse Biosciences is a high-risk medtech story. The bull case is simple. Its nanosecond pulsed-field ablation, or nsPFA, could remove unwanted cells without heat. If that proves faster and safer than older burn or freeze tools, the platform could matter in soft tissue and heart procedures.
The company has crossed an important line into commercial sales. In Q2 2026, Pulse reported $434,000 of product revenue from limited market release sales of its Vybrance percutaneous electrode system. That is a sequential increase from $400,000 in the first quarter.
The bear case remains serious. Vybrance revenue is tiny, and the larger heart programs need long clinical trials and FDA review. The company raised cash to reach over $100 million in the second quarter, but high spending will continue as it funds trials and prepares for a wider launch.
The next proof points are clear. Watch the NANOPULSE-AF pivotal catheter study, which now targets early October 2026 for completion, and upcoming regulatory filings in Europe and the United States.
Console plus electrodes
Pulse sells a system, not a pill. Its nPulse platform uses a console and procedure tools that deliver very short electric pulses. The idea is to make money from the installed system and from disposable electrodes used in procedures.
The first commercial revenue came from Vybrance, a percutaneous needle electrode used with the nPulse Console for soft tissue ablation. The launch is limited, so current sales do not yet prove broad demand.
Most of the company value is still tied to future uses, especially atrial fibrillation. That market is large, but crowded. Doctors already use thermal ablation systems from major device companies, so Pulse must prove its tools are not only novel, but clearly better.
One launch, several shots
nPulse System
This is the core nsPFA energy platform, formerly called CellFX. It delivers nanosecond electric pulses through Pulse devices.
Vybrance Percutaneous Electrode System
Vybrance is FDA 510(k) cleared for soft tissue ablation. It produced the company's initial product revenue in early 2026 during a limited market release.
PRECISE BTN trial
This pivotal trial is meant to support use of Vybrance for benign thyroid nodules. It could help turn a narrow launch into a more specific commercial use case.
nPulse Cardiac Clamp
The clamp is being studied for surgical treatment of atrial fibrillation. Pulse received IDE approval in September 2025 and enrolled the first patient in the pivotal study.
nPulse 360° Cardiac Catheter
The catheter is a heart ablation program for atrial fibrillation. The FDA approved the IDE in December 2025, and first patients were treated in April 2026.
Revenue is one small stream
Pulse does not describe a broad multi-segment revenue mix. For Q2 2026, all reported revenue came from limited market release commercial sales of Vybrance.
What can break it
Cash burn and dilution
High impact · High oddsPulse still needs to fund clinical trials, product work, regulatory filings, and a commercial launch. The company ended Q2 2026 with over $100 million in cash after an ATM capital raise. If spending stays high while revenue remains small, it may need more capital, which could dilute shareholders.
Cardiac FDA setbacks
High impact · Medium oddsThe biggest upside is in atrial fibrillation, but those uses need stronger clinical evidence. The company increased its NANOPULSE-AF enrollment target to 164 patients. A trial delay, weak result, or FDA request for more data would hurt the thesis.
Vybrance launch stalls
Medium impact · Medium oddsQ2 2026 product revenue was only $434,000, so the launch is still very early. Hospitals and doctors may test the product but not adopt it widely. If repeat usage stays low, the soft tissue business may not fund the larger pipeline.
Technology does not separate
High impact · Medium oddsPulse depends heavily on nsPFA working better than existing ablation tools. Incumbent thermal ablation systems already have trained doctors, installed equipment, and clinical history. If Pulse cannot show clear safety, speed, or outcome gains, adoption could be slow.
Control sits with one insider
Medium impact · High oddsRobert W. Duggan held 71.6 percent beneficial ownership in the 2025 10-K/A. That gives one insider large voting power over company decisions. Minority shareholders have less ability to influence strategy, pay, financing, or governance.
In one breath
What does Pulse Biosciences actually sell?
Pulse sells the nPulse platform and related ablation tools. Its first commercial product revenue came from Vybrance, a percutaneous electrode used for soft tissue ablation.
Why do investors care about atrial fibrillation?
Atrial fibrillation is a large heart rhythm market where ablation is already used. Pulse is trying to prove its cardiac clamp and catheter can treat tissue without heat, but those products are still in clinical development.
Is Pulse Biosciences profitable?
The provided filings and thesis frame Pulse as an early commercial company with high cash burn. Q2 2026 revenue was only $434,000, so the company is still mainly a clinical and regulatory execution story.
What changed most recently?
In Q2 2026, the company pulled forward its NANOPULSE-AF pivotal catheter trial completion date by three months to October 2026 due to fast enrollment. It also raised capital, ending the quarter with over $100 million in cash.
